Pancreatic adenocarcinoma (PDAC) is an abysmal disease, with a poor clinical outcome, largely due to limited life-extending treatments for patients. Notoriously, PDAC displays a T cell-suppressive tumor microenvironment where underlying molecular mechanisms that lead to this phenotype remain poorly understood. To unr...
Kimberly A. Kelly, Cody L. Wolf, Roxanne K. Ruiz et al.· Cancer Research· 0 citations
Overall, this study identifies lymphoid and myeloid cell contributions to response to treatment with HDAC inhibitors and immune checkpoint blockade, providing a framework for discovering interactions driving responses in complex TMEs.
E. Gonzalez, J. Kreger, Ying-Tong Liu et al.· Cancer Research· 0 citations
Plectin is identified as a biomarker of aggressive disease in PDAC, with high plectin expression associated with decreased T cell infiltration, and anti-CSP treatment reinstates antitumor immunity and decreases tumor volume in vivo.
Cody L. Wolf, Roxanne K. Ruiz, Sokchea Khou et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.